CD86 and neoplasm: However, MET PTX could increase dendritic cells percentage both in the spleen and tumor and upregulate the expression of CD80 and CD86 co-stimulatory makers compared to control group (P < 0.05), while MTD PTX could reduce dendritic cells percentage and downregulate the expression of co-stimulatory makers CD80 and CD86 compared to control group (P < 0.05), with a significant difference between MET PTX and MTD PTX group (P < 0.05).